Dr Andrea Bernabeu presents the results of the ADAPT-1 study on personalised ovarian stimulation at ESHRE.

Dr. Andrea Bernabeu, medical director of Grupo Instituto Bernabeu, will be one of the keynote speakers at the closing session of the ESHRE annual congress. In her intervention, she will present the results of the multicentre study ADAPT-1, focused on the use of follitropin delta in in vitro fertilisation (IVF) treatments under a conventional dosing approach.

The study, entitled ‘ADAPT-1: A multicentre, randomised, assessor-blind comparison of ovarian stimulation with follitropin delta versus follitropin alfa for in vitro fertilisation using conventional dosing regimens’, compares the performance of follitropin delta versus follitropin alfa using dosing schedules equivalent to those commonly used in clinical practice.

The research assumes that personalised medicine is a promising approach to optimising IVF outcomes, and in this context follitropin delta is of particular relevance. Unlike other recombinant FSH hormones, its dosage is designed to be tailored to individual patient characteristics, mainly body weight and anti-Müllerian hormone (AMH) levels.

The trial evaluated the efficacy of administering 15 µg/day follitropin delta versus 225 IU/day follitropin alfa, a range considered clinically equivalent. The primary objective was to compare the number of oocytes retrieved, while secondary objectives focused on safety and tolerability parameters during controlled ovarian stimulation.

This study marks a step forward in the practical application of individualised treatments in reproductive medicine, and provides solid scientific evidence to further improve ovarian stimulation protocols in IVF patients.